Results 181 to 190 of about 5,926 (192)

Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial

Annals of Oncology, 2018
J Ettl, S Hurvitz, MIGUEL Martin
exaly  

Clinical pharmacology and therapeutic applications of talazoparib: a comprehensive review

Cancer Chemotherapy and Pharmacology
Saphal Lakshmi, Pasupulati, Katiboina, Srinivasa Rao, Sushil, Sharma, C, Madhavrao, Gaurav, Rangari, Arup Kumar, Misra, L V Simhachalam, Kutikuppala, T, Devika, Sandhya Rani, Sarikonda   +8 more
openaire   +2 more sources

Overexpression of ABCC1 and ABCG2 confers resistance to talazoparib, a poly (ADP-Ribose) polymerase inhibitor

Drug Resistance Updates
Qiu-Xu Teng, John Würpel
exaly  

Aciclovir/Gemtuzumab-ozogamicin/Talazoparib

Reactions Weekly
openaire   +1 more source

A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer

Case Medical Research, 2019
openaire   +1 more source

Neu bei mCRPC: Talazoparib + Enzalutamid

Oncology Research and Treatment
openaire   +1 more source

Investigational PARP Inhibitor Talazoparib Shows Clinical Benefit

Oncology Times, 2018
openaire   +1 more source

Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma

Case Medical Research, 2019
openaire   +1 more source

Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts

Case Medical Research, 2019
openaire   +1 more source

Talazoparib in Advanced Breast Cancer With a Germline BRCA Mutation

Oncology Times, 2019
openaire   +1 more source